Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
AOD 9604 long-term outlook The long-term safety data for AOD 9604 is limited because the clinical development program was terminated
Lee incorporates weight loss injections into a comprehensive lifestyle program aimed at long-term, sustainable weight management
Most people with moderate to severe high blood pressure will still need their blood pressure medications along with GLP-1 treatment
Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)
US$ 24.01
US$ 20.10
US$ 29.15
